Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
russurban Followed KIQ23 hours ago
russurban Placed a 'Buy' Sentiment on VXRTMore than a week ago
russurban Placed a 'Buy' Sentiment on OTLKMore than a week ago
anonusers Placed a 'Sell' Sentiment on UNVC5 days ago
anonusers Placed a 'Buy' Sentiment on HOMEMore than a week ago
anonusers Placed a 'Sell' Sentiment on WBAMore than a week ago
stockarticles Placed a 'Buy' Sentiment on BBMore than a week ago
stockarticles Followed BBMore than a week ago
stockarticles Placed a 'Buy' Sentiment on SNAPMore than a week ago
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  VXRT  •  OTLK  •  PINS  •  BB  •  TWTR  •  CGC  •  ARCI  •  LULU  •  SNAP  •  IRBT

MESO Quietly Completed Key Deal with Tasly


MESO, Mesoblast Limited

The still undiscovered Mesoblast completed a key strategic partnership.

Released on Friday, October 12, 2018, 9:40 PM ET
by Email Russ UrbanContact SpeculatingStocks

Pittsburgh, PA (SpeculatingStocks) - Mesoblast Limited (NASDAQ:MESO) announced on Friday, October 12th the completion of a strategic cardiovascular product partnership with Tasly Pharmaceutical Group. MESO receives $40 million upfront from Tasly Pharma and on successful achievement of the agreement, Mesoblast would then receive $25 million and royalties as well as other milestone payments.

This is a sweetheart deal for MESO for a company that is valued at $672 million. Mesoblast will have to see through the development of MPC-150-IM for the chronic heart failure and MPC-25-IC acute myocardial infarction. Tasly is covering costs as they pertain to China commercialization and other activities such as development and manufacturing.

There are over 200,000 cases of chronic heart failure and 3 million cases of acute myocardial infarction in the US a year. Mesoblast has a massive potential market on its hands if it can achieve the goals that the Mesoblast / Tasly partnership has set up. Best of all, MESO has a reputable partner to help push and see it through. Tasly Pharmaceutical is listed on the Shanghai as a $31.5 billion company.

MESO is still relatively undiscovered with volume on Friday of only 49,560 shares. There is room for institutions to move into MESO with current institutional ownership of only 2.72%. Cash isn't going to be an issue for MESO. The company can purely focus on achieving its goals set up in the Tasly partnership.

MESO's chart has corrected and the stock looks primed to start a new uptrend. From a fundamental and technical perspective, Mesoblast is ready to wow investors that come across it.

Join the discussion of stocks and topics mentioned in this article within:

"The Poor Man's Bloomberg Terminal":

Discover more stocks on the:

⇒ About the Author of this News Article:

Russ Urban has been following the stock market for over 18 years and holds a Bachelor's Degree in Finance. From a young age, he watched CNBC with a keen eye and became obsessed with the market and technology. Russ Urban has written hundreds of stock articles and stock picks through the years since he founded, Inc. in 2006 and holds strong faith in the power of the markets and capitalism.

 If you like what you read, please share this article on social media via top right buttons in the header of this page or share in other ways. Thank you. We depend on the help of our visitors. Much appreciated.